Tissue-selective ablation.
Unlike thermal energy applications, the FARAPULSE Pulsed Field Ablation System uses a proprietary waveform to ablate cardiomyocytes which have a higher susceptibility to electric field exposure than surrounding tissues — despite exposure to the field.²
Uncover the key successes of PFA with Prof. Miklavcic as he explains how a deeper understanding of biophysics can enhance clinical practice.
Discover more about PFA biophysics with Prof. Guerra
Proven procedural prescription for successful PVI.
Pulsed field ablation is highly parameter-dependent, and slight variations in polarity, waveform, catheter electrodes, pulse characteristics, or applications can be the difference between acute or chronic success.3 The FARAPULSE Pulsed Field Ablation System was optimised through years of iterations to define and validate the dose with catheter, waveform, and application sequence.
Pulmonary Vein Durability on Remapping¹
Prospective Remaps at 93 ± 30 days
All three cohorts showed 100% acute PVs isolated, though lesion durability varied significantly at remap (~3 months). Acute isolation alone is not enough to assure durable lesions — remapping data validates the FARAPULSE Pulsed Field Ablation System’s optimal dosing and applications for long-term success.¹
Learn from your peers! Prof. Széplaki shares what to expect from the Academy Programme and the benefits of proctoring.
Learn about PFA from the experts.
Dr Guerra and Prof. Scherr present the clinical implication of PFA biophysics and review PFA in clinical practice to optimally manage AF patients.
Listen to Brendan Koop, Senior Fellow, R&D in Electrophysiology, to discover how the FARAPULSE PFA system and FARAWAVE™ catheter work.
Discover how FARAPULSE PFA increased procedure volumes and predictability for Prof. Szeplaki and team.
Prof. Kars Neven presents an overview of PFA, its history, pre-clinical data, system design, and more.
On-demand online training.
Put your understanding of pulsed field ablation to the test with a guided overview course on the EDUCARE platform — accessible 24/7 from your desktop, laptop, or mobile device.
References:
1. Reddy VY, Dukkipati SR, Neuzil P, et al. Pulsed field ablation of paroxysmal atrial fibrillation: 1-year outcomes of IMPULSE, PEFCAT, and PEFCAT II. JACC Clin Electrophysiol. 2021 May;7(5):614-27.
2. Reddy VY, Neuzil P, Koruth JSS, et al. Pulsed field ablation for pulmonary vein isolation in atrial fibrillation. J Am Coll Cardiol. 2019 Jul 23;74(3):315-26.
3. Verma A, Asivatham SJ, Deneke T, et al. Primer on pulsed electrical field ablation: Understanding the Benefits and Limitations. Circ Arrhythm Electrophysiol. 2021 Sept;14(9):e010086.
1. Reddy VY, Dukkipati SR, Neuzil P, et al. Pulsed field ablation of paroxysmal atrial fibrillation: 1-year outcomes of IMPULSE, PEFCAT, and PEFCAT II. JACC Clin Electrophysiol. 2021 May;7(5):614-27.
2. Reddy VY, Neuzil P, Koruth JSS, et al. Pulsed field ablation for pulmonary vein isolation in atrial fibrillation. J Am Coll Cardiol. 2019 Jul 23;74(3):315-26.
3. Verma A, Asivatham SJ, Deneke T, et al. Primer on pulsed electrical field ablation: Understanding the Benefits and Limitations. Circ Arrhythm Electrophysiol. 2021 Sept;14(9):e010086.
CAUTION:The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device. or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries.This material not intended for use in France.